{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:13:25Z","timestamp":1780524805374,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EU Horizon 2020"},{"DOI":"10.13039\/100010665","name":"Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["956758"],"award-info":[{"award-number":["956758"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The HealthHolland program TARGlycan","award":["TKI-LSH-DT2O22LUMC:2022\u201302"],"award-info":[{"award-number":["TKI-LSH-DT2O22LUMC:2022\u201302"]}]},{"name":"EU HORIZON-CSA program GLYCOTwinning","award":["101079417"],"award-info":[{"award-number":["101079417"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increased sialylation of tumour cells, which favours tumour growth and immune evasion, has been described using in vitro and in vivo models, leading to the first in-human clinical trial targeting sialylation in cancer. One important limitation is that the biology of sialic acids and their receptors (Siglecs), which have been considered as immune checkpoints, is different between mice and human. Hence, it is crucial to fully describe and investigate sialic acids and Siglecs expression in animal models, to define their advantages and limitations. Here, we determined the sialylation profile of the widely-used B16OVA melanoma mouse model using flow cytometry and glycomics. B16OVA cells express Siglec-E-binding sialoglycans, therefore we explored Siglec-E expression across various tissues from tumour-bearing mice. We identified that Siglec-E is expressed on myeloid cells and CD8+ T cells in the tumour microenvironment. However, in spleen, blood and tumour-draining lymph nodes not only CD8+ but also CD4+ T cells expressed Siglec-E. Interestingly, Siglec-E+ and Siglec-E\u2212 T cells presented distinct expression of PD-1 across tissues, suggesting different regulation mechanisms for the expression of these immune checkpoints. Our work provides an investigation of the sialoglycans on B16OVA cells and the expression of their receptor Siglec-E across tissues, which is of importance for future therapeutic studies targeting the sialic acids-Siglec axis, especially in combination with anti-PD-1 therapies.<\/jats:p>","DOI":"10.1093\/glycob\/cwag041","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:51:15Z","timestamp":1780055475000},"source":"Crossref","is-referenced-by-count":0,"title":["Sialylation profile and Siglec-E expression across tissues in the B16OVA melanoma mouse model"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-5321","authenticated-orcid":false,"given":"Magali","family":"Coccimiglio","sequence":"first","affiliation":[{"name":"Department of Molecular Cell Biology & Immunology, Amsterdam UMC Location VUmc , De Boelelaan 1108, 1081 HZ, 1007 MB, Amsterdam ,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam , De Boelelaan 1118, 1081 HV, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam institute for Immunology and Infectious diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center , Room P-01-064, Building 1 (route 920), 2333 ZA, Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Olesek","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology & Immunology, Amsterdam UMC Location VUmc , De Boelelaan 1108, 1081 HZ, 1007 MB, Amsterdam ,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam , De Boelelaan 1118, 1081 HV, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam institute for Immunology and Infectious diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Goossens-Kruijssen","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology & Immunology, Amsterdam UMC Location VUmc , De Boelelaan 1108, 1081 HZ, 1007 MB, Amsterdam ,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam , De Boelelaan 1118, 1081 HV, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam institute for Immunology and Infectious diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"de Haan","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Metabolomics, Leiden University Medical Center , Room P-01-064, Building 1 (route 920), 2333 ZA, Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Chiodo","sequence":"additional","affiliation":[{"name":"Italian National Research Council, Institute of Biomolecular Chemistry , Via Campi Flegrei, 34, 80078, Pozzuoli, Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"van Kooyk","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology & Immunology, Amsterdam UMC Location VUmc , De Boelelaan 1108, 1081 HZ, 1007 MB, Amsterdam ,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam , De Boelelaan 1118, 1081 HV, Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam institute for Immunology and Infectious diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026060317585193800_ref1","doi-asserted-by":"publisher","first-page":"101117","DOI":"10.1016\/j.mam.2022.101117","article-title":"Discovery, classification, evolution and diversity of Siglecs","volume":"90","author":"Angata","year":"2023","journal-title":"Mol Asp Med"},{"key":"2026060317585193800_ref2","volume-title":"Essentials of Glycobiology","author":"Angata","year":"2022","edition":"4th"},{"issue":"11","key":"2026060317585193800_ref3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumour immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat Immunol"},{"issue":"13","key":"2026060317585193800_ref4","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic acid blockade suppresses tumour growth by enhancing T-cell-mediated tumour immunity","volume":"78","author":"Bull","year":"2018","journal-title":"Cancer Res"},{"issue":"12","key":"2026060317585193800_ref5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"5","key":"2026060317585193800_ref6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505","article-title":"Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumour microenvironment","volume":"7","author":"Haas","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"26","key":"2026060317585193800_ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumour immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2026060317585193800_ref8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumour immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"2026060317585193800_ref9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"Laubli","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"46","key":"2026060317585193800_ref10","doi-asserted-by":"publisher","first-page":"28743","DOI":"10.1073\/pnas.2014207117","article-title":"Spatial and temporal diversity of glycome expression in mammalian brain","volume":"117","author":"Lee","year":"2020","journal-title":"Proc Natl AcadSci USA"},{"key":"2026060317585193800_ref11","volume-title":"Essentials of Glycobiology [internet]","author":"Lewis","year":"2022","edition":"4th edition ed."},{"key":"2026060317585193800_ref12","doi-asserted-by":"publisher","first-page":"101893","DOI":"10.1016\/j.smim.2024.101893","article-title":"Sialic acid and Siglec receptors in tumour immunity and immunotherapy","volume":"74-75","author":"Mantuano","year":"2024","journal-title":"Semin Immunol"},{"issue":"2","key":"2026060317585193800_ref13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molcel.2019.05.017","article-title":"An atlas of human glycosylation pathways enables display of the human Glycome by gene engineered cells","volume":"75","author":"Narimatsu","year":"2019","journal-title":"Mol Cell"},{"issue":"40","key":"2026060317585193800_ref14","doi-asserted-by":"publisher","first-page":"34522","DOI":"10.1074\/jbc.M111.243410","article-title":"Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E","volume":"286","author":"Redelinghuys","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"2026060317585193800_ref15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Rodriguez","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2026060317585193800_ref16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2026060317585193800_ref17","doi-asserted-by":"publisher","first-page":"109037","DOI":"10.1016\/j.isci.2024.109037","article-title":"The transcriptional landscape of glycosylation-related genes in cancer","volume":"27","author":"Rodriguez","year":"2024","journal-title":"iScience"},{"key":"2026060317585193800_ref18","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90(1)","author":"Stanczak","year":"2023","journal-title":"Mol Asp Med"},{"issue":"11","key":"2026060317585193800_ref19","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1172\/JCI120612","article-title":"Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells","volume":"128","author":"Stanczak","year":"2018","journal-title":"J Clin Invest"},{"issue":"669","key":"2026060317585193800_ref20","doi-asserted-by":"publisher","first-page":"eabj1270","DOI":"10.1126\/scitranslmed.abj1270","article-title":"Targeting cancer glycosylation repolarizes tumour-associated macrophages allowing effective immune checkpoint blockade","volume":"14","author":"Stanczak","year":"2022","journal-title":"Sci Transl Med"},{"issue":"10","key":"2026060317585193800_ref21","doi-asserted-by":"publisher","first-page":"110641","DOI":"10.1016\/j.jbc.2025.110641","article-title":"Sialic acids in cancer biology and immunity-recent advancements","volume":"301","author":"Vliet","year":"2025","journal-title":"J Biol Chem"},{"key":"2026060317585193800_ref22","doi-asserted-by":"publisher","first-page":"828916","DOI":"10.3389\/fcell.2022.828916","article-title":"Siglec receptors modulate dendritic cell activation and antigen presentation to T cells in cancer","volume":"10(1)","author":"Wang","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"24","key":"2026060317585193800_ref23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J Clin Invest"},{"issue":"5","key":"2026060317585193800_ref24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2026060317585193800_ref25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41467-025-68186-2","article-title":"A comprehensive N-glycoproteome atlas reveals tissue-specific glycan remodeling but non-random structural microheterogeneities","volume":"17","author":"Wu","year":"2026","journal-title":"Nat Commun"}],"container-title":["Glycobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/glycob\/advance-article-pdf\/doi\/10.1093\/glycob\/cwag041\/68442932\/cwag041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/glycob\/article-pdf\/36\/7\/cwag041\/68442932\/cwag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/glycob\/article-pdf\/36\/7\/cwag041\/68442932\/cwag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:58:57Z","timestamp":1780523937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/glycob\/article\/doi\/10.1093\/glycob\/cwag041\/8699376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5,22]]}},"URL":"https:\/\/doi.org\/10.1093\/glycob\/cwag041","relation":{},"ISSN":["1460-2423"],"issn-type":[{"value":"1460-2423","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,22]]},"article-number":"cwag041"}}